|By PR Newswire||
|April 9, 2014 06:28 AM EDT||
NEW YORK, April 9, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022
The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.
For the treatment of CD, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASAs. GlobalData's physician survey showed that these drugs are the mainstay of treatment for mild to moderate CD in India, as well as at earlier lines of therapy for severe disease. While Indian physicians commonly prescribe domestic generics and biosimilars, our primary research revealed that biosimilars were not readily available to those with CD.
- Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India Crohn's disease market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in India.
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 16
3.3 Prognosis 17
3.4 Quality of Life 18
4 Disease Management 19
4.1 Treatment Overview 20
4.2 India 25
4.2.1 Diagnosis 25
4.2.2 Clinical Practice 25
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 28
5.3 Product Profiles - Major Brands 29
5.3.1 Remicade (infliximab) 29
5.3.2 Other Marketed Products 35
6 Opportunity and Unmet Need 36
6.1 Overview 36
6.2 Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach 37
6.3 More Therapies for Anti-TNF-Refractory Patients 38
6.4 Unmet Needs Gap Analysis 39
6.5 Targeted Therapies 40
6.6 Predictive Tools for Early Diagnosis and Treatment 41
7 Pipeline Assessment 42
7.1 Overview 42
7.2 Promising Drugs in Clinical Development 42
7.3 Other Late-Stage Pipeline Products 44
7.3.1 Cx601 44
7.3.2 RHB-104 (clarithromycin + clofazimine + rifabutin) 46
8 Market Outlook 51
8.1 Global Markets 51
8.1.1 Drivers and Barriers - Global Issues 51
9 India 56
9.1 Forecast 56
9.2 Key Events 58
9.3 Drivers and Barriers 59
9.3.1 Driver: Continued investment in the national healthcare system and services 59
9.3.2 Driver: Sizeable CD patient population that will increase over the coming decade 59
9.3.3 Barrier: Loose intellectual property policies present a major challenge for developers with novel drugs 60
9.3.4 Barrier: Limited access to and the high price point of CD therapies, coupled with many Indians' belief in traditional medicine, negatively impacts branded drug sales 60
9.3.5 Barrier: Downward pricing pressure limits drug sales growth 61
10 Appendix 62
10.1 Bibliography 62
10.2 Abbreviations 67
10.3 Methodology 71
10.4 Forecasting Methodology 71
10.4.1 Diagnosed CD Patients 71
10.4.2 Percent Drug-Treated Patients 72
10.4.3 Drugs Included in Each Therapeutic Class 72
10.4.4 General Pricing Assumptions 72
10.4.5 Individual Drug Assumptions 74
10.4.6 Generic Erosion 74
10.5 Physicians and Specialists Included in This Study 75
10.6 Primary Research - Prescriber Survey 76
10.7 About the Authors 77
10.7.1 Author/Reviewer 77
10.7.2 Global Head of Healthcare 77
10.8 About GlobalData 78
10.9 Disclaimer 78
1.1 List of Tables
Table 1: Symptoms of CD 17
Table 2: Treatment Guidelines for CD 21
Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013 23
Table 4: Leading Branded Drugs Used to Treat CD 29
Table 5: Product Profile - Remicade 31
Table 6: Remicade SWOT Analysis, 2013 34
Table 7: Summary of the Minor Therapeutic Classes in CD, 2013 35
Table 8: Overall Unmet Needs in CD - Current Level of Attainment 37
Table 9: Clinical Unmet Needs in CD - Gap Analysis, 2013 40
Table 10: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013 42
Table 11: Comparison of Therapeutic Classes in Development for CD, 2013 43
Table 12: Product Profile - Cx601 45
Table 13: Cx601 SWOT Analysis, 2013 46
Table 14: Product Profile - RHB-104 48
Table 15: RHB-104 SWOT Analysis, 2013 50
Table 16: Global CD Market - Drivers and Barriers, 2012-2022 51
Table 17: Sales Forecasts ($) for CD in India, 2012-2022 57
Table 18: Key Events Impacting Sales for CD in India, 2012-2022 58
Table 19: CD Market in India - Drivers and Barriers, 2012-2022 59
Table 20: Physicians Surveyed, By Country 76
1.2 List of Figures
Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right) 13
Figure 2: Potential Biologic Drug Targets for CD 16
Figure 3: Patient Care Path for CD 22
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022 43
Figure 5: Sales for CD in India by Drug Class, 2012-2022 58
To order this report: PharmaPoint: Crohn's Disease - India Drug Forecast and Market Analysis to 2022
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
Aug. 29, 2015 06:00 AM EDT Reads: 363
U.S. companies are desperately trying to recruit and hire skilled software engineers and developers, but there is simply not enough quality talent to go around. Tiempo Development is a nearshore software development company. Our headquarters are in AZ, but we are a pioneer and leader in outsourcing to Mexico, based on our three software development centers there. We have a proven process and we are experts at providing our customers with powerful solutions. We transform ideas into reality.
Aug. 29, 2015 05:45 AM EDT Reads: 498
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
Aug. 29, 2015 05:30 AM EDT Reads: 335
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
Aug. 29, 2015 05:00 AM EDT Reads: 399
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
Aug. 29, 2015 03:00 AM EDT Reads: 465
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Aug. 28, 2015 11:45 PM EDT Reads: 401
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Aug. 28, 2015 11:30 PM EDT Reads: 831
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
Aug. 28, 2015 09:00 PM EDT Reads: 299
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
Aug. 28, 2015 07:45 PM EDT Reads: 184
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Aug. 28, 2015 06:00 PM EDT Reads: 313
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Aug. 28, 2015 05:30 PM EDT Reads: 407
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
Aug. 28, 2015 03:45 PM EDT Reads: 168
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
Aug. 28, 2015 03:15 PM EDT
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
Aug. 28, 2015 03:01 PM EDT
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Aug. 28, 2015 02:15 PM EDT Reads: 414